Role of miR-483 in digestive tract cancers: from basic research to clinical value
Wei Zhou(Broad Institute), Liu Hong(National Clinical Research Center for Digestive Diseases), Li Zeng(Ministry of Education), Hongwei Zhang(University of Massachusetts Chan Medical School), Hu Wang(The University of Texas at San Antonio Health Science Center), Lei Zhang(Hebei Medical University), Wanli Yang(National Clinical Research Center for Digestive Diseases), Jinqiang Liu(University of California, Irvine), Jiaojiao Ma(Sun Yat-sen University), Zhenyu Han(Xijing Hospital)
Cited by 23
Related Papers
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
miRNA-223 Promotes Gastric Cancer Invasion and Metastasis by Targeting Tumor Suppressor EPB41L3
|Molecular Cancer Research|2011|361
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells
|Proceedings of the National Academy of Sciences|2011|256
Global CNS Transduction of Adult Mice by Intravenously Delivered rAAVrh.8 and rAAVrh.10 and Nonhuman Primates by rAAVrh.10
|Molecular Therapy|2014|211
MicroRNA-regulated, Systemically Delivered rAAV9: A Step Closer to CNS-restricted Transgene Expression
|Molecular Therapy|2010|168